|
|
|
|
|
|
| Broadens Distribution Network and Accelerates Growth |
HONG KONG, June 27, 2016 - (ACN Newswire) - Uni-Bio Science Group Ltd ("Uni-Bio Science" or the "Group"; HKEx: 690) today announced that it signed a strategic alliance agreement with China Resources Zizhu Pharmaceutical Co., Ltd ("China Resources Zizhu"), a wholly owned subsidiary of China Resource Pharmaceuticals Group, which focuses on development, manufacture and marketing of ophthalmology and reproductive health drugs in China. China Resouces Zhizhu has gained several years of experience in the ophthalmologic and reproductive health pharmaceutical segments. Under the agreement, China Resources Zizhu is granted the sole distribution and promotion rights of GeneSoft and will include the drug within its existing hospital network in Mainland China for a minimum of five years, with an option to renew the contract for the following five years.
 | | Mr. KOH Phee Wah, CEO of China Operations of Uni-Bio Science (first row, left) and Mr. WU Jun, Senior Deputy General Manager of China Resources Pharmaceutical Group and Chairman of China Resources Zizhu (first row, right), today sign a strategic alliance agreement related to the sole distribution and promotion rights of GeneSoft in China.
|
GeneSoft is an ophthalmic solution containing a derivative of recombinant human epidermal growth factor (rhEGF) which enhances the healing of cornea wounds by promoting corneal epithelium regeneration. The mechanism of action is unique and therefore highly applicable to a wide range of ophthalmology indications, including dry eyes, and trauma after ocular surgery (e.g. LASIK). According to IMS, China's ophthalmology market size has close to tripled in the past five years to RMB4.0 billion in 2014. In the near future, ophthalmology will continue to be one of the fastest growing indications in China due to aging population and prolonged use of smartphones and computers on a daily basis.
Under the partnership, GeneSoft has immediate access to China Resources Zizhu's network for commercializing the drug, a distribution platform with a proven track record and a seasoned sales and marketing team. Currently, GeneSoft is reimbursed in Jilin and Yunnan provinces as well as Tianjin municipality. Uni-Bio Science believes that through leveraging China Resources Zizhu's extensive distribution network and expertise in sales and marketing, distribution of GeneSoft can be expanded to new regions more quickly, thereby driving further business growth.
Mr. KOH Phee Wah, CEO of China Operations of Uni-Bio Science, said: "Creating a partnership model to expand our business has been a key direction in mapping out our new strategy since 2015. I am pleased with the latest partnership with the reputable industry player China Resources Zizhu, to accelerate the penetration of GeneSoft in the PRC market. This alliance also demonstrates China Resources Zizhu's recognition both of our Group as well as the competitive advantages and the potential of our drug. By leveraging China Resources Zizhu's extensive distribution network, proven track record and commercialization expertise, we are confident that our partnership can boost the revenues generated by our quality drug as the partnership realises its potential to improve its performance in the near future."
Mr. WU Jun, Senior Deputy General Manager of China Resources Pharmaceutical Group and Chairman of China Resources Zizhu, said, "China Resources Zizhu, a wholly-owned subsidiary of China Resources Pharmaceutical Group, is a leader in the reproductive health pharmaceuticals market in China and has achieved rapid development in the R&D and marketing of ophthalmologic drugs. And in recent years, China Resources Zizhu has actively expanded in the ophthalmologic treatment segment. Overall, sales of our major ophthalmologic products grew rapidly in 2015 compared to 2014.
Through our cooperation with Uni-Bio Science, we hope to enlarge the market share of GeneSoft in China and on the other hand, to add product types to our portfolio through agency arrangement, China Resources Zizhu is able to speed up establishing presence in the ophthalmology market."
About Uni-Bio Science Group Limited (SEHK: 0690)
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.
About China Resources Zizhu Pharmaceutical Co., Limited
China Resources Zizhu is a wholly owned subsidiary of China Resources Pharmaceutical Group Limited, and the parent ranks second in terms of overall capabilities among domestic players in China. With the mission "Better Life Together", China Resources Pharmaceutical Group aims to become the "leading pharmaceutical company in China".
China Resources Zizhu is a high-tech company that mainly produces family-planning, reproductive health and ophthalmologic pharmaceutical products, as well as active pharmaceutical ingredients (API). With more than four decades of experience in research and development of pharmaceutical products, the company was among the first to be named a key enterprise in the Beijing Biomedical Industry Development Project (G20 Project).
About GeneSoft
GeneSoft is a colourless and transparent ophthalmic solution containing a derivative of recombinant human epidermal growth factor (rhEGF) for topical use which enhances the healing of cornea wounds by promoting corneal epithelium regeneration. The rhEGF used in GeneSoft contains a patented extra three amino acids in the N-terminus, which confer original rhEGF with additional commercial benefits, including better stability. GeneSoft is approved by the CFDA as a class I bio product in 2004 for a very wide range of lucrative ophthalmology indications related corneal epithelial defects. These include eye trauma, ocular surgery, dry eye with recurrent superficial punctuate keratitis, moderate chemical burn, etc. Over the last four years, Uni-Bio Science's sales of EGF-related products (GeneTime and GeneSoft) have registered a CAGR of 21.9%, representing sales of HK$82.0 million as of 31 December 2015.
Media Enquiries:
Strategic Financial Relations Limited
Veron Ng Phone: +852 2864 4831 Email: veron.ng@sprg.com.hk
Angelus Lau Phone: +852 2864 4805 Email: angelus.lau@sprg.com.hk
Phoebe Li Phone: +852 2864 4862 Email: phoebe.li@sprg.com.hk
Fax: +852 2527 1196
Topic: Press release summary
Source: Uni-Bio Science Group Limited
Sectors: Daily Finance, Daily News
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
